These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 10332054)
1. Nonparametric analysis of the absorption profile of octreotide in rabbits from long-acting release formulation OncoLAR. Comets E; Mentré F; Nimmerfall F; Kawai R; Mueller I; Marbach P; Vonderscher J J Control Release; 1999 May; 59(2):197-205. PubMed ID: 10332054 [TBL] [Abstract][Full Text] [Related]
2. Modeling the kinetics of release of octreotide from long-acting formulations injected intramuscularly in rabbits. Comets E; Mentré F; Kawai R; Nimmerfall F; Marbach P; Vonderscher J J Pharm Sci; 2000 Sep; 89(9):1123-33. PubMed ID: 10944377 [TBL] [Abstract][Full Text] [Related]
3. Sandostatin LAR in acromegaly: a 6-week injection interval suppresses GH secretion as effectively as a 4-week interval. Biermasz NR; van den Oever NC; Frölich M; Arias AM; Smit JW; Romijn JA; Roelfsema F Clin Endocrinol (Oxf); 2003 Mar; 58(3):288-95. PubMed ID: 12608933 [TBL] [Abstract][Full Text] [Related]
4. Comparison of monthly intramuscular injections of Sandostatin LAR with multiple subcutaneous injections of octreotide in the treatment of acromegaly; effects on growth hormone and other markers of growth hormone secretion. Hunter SJ; Shaw JA; Lee KO; Wood PJ; Atkinson AB; Bevan JS Clin Endocrinol (Oxf); 1999 Feb; 50(2):245-51. PubMed ID: 10396369 [TBL] [Abstract][Full Text] [Related]
5. Depot long-acting somatostatin analog (Sandostatin-LAR) is an effective treatment for acromegaly. Stewart PM; Kane KF; Stewart SE; Lancranjan I; Sheppard MC J Clin Endocrinol Metab; 1995 Nov; 80(11):3267-72. PubMed ID: 7593436 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic and technical comparison of Sandostatin® LAR® and other formulations of long-acting octreotide. Petersen H; Bizec JC; Schuetz H; Delporte ML BMC Res Notes; 2011 Sep; 4():344. PubMed ID: 21906300 [TBL] [Abstract][Full Text] [Related]
8. Octreotide long-acting release (LAR): a review of its use in the management of acromegaly. McKeage K; Cheer S; Wagstaff AJ Drugs; 2003; 63(22):2473-99. PubMed ID: 14609359 [TBL] [Abstract][Full Text] [Related]
19. Octreotide long-acting release (LAR). A review of its pharmacological properties and therapeutic use in the management of acromegaly. Gillis JC; Noble S; Goa KL Drugs; 1997 Apr; 53(4):681-99. PubMed ID: 9098666 [TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics, pharmacodynamics, and safety of microencapsulated octreotide acetate in healthy subjects. Chen T; Miller TF; Prasad P; Lee J; Krauss J; Miscik K; Kalafsky G; McLeod JF J Clin Pharmacol; 2000 May; 40(5):475-81. PubMed ID: 10806600 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]